Compare Krispy Kreme Inc (DNUT) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs DexCom, Inc. — how do they compare? Krispy Kreme Inc trades at $3.31 (market cap $574.09M), while DexCom, Inc. trades at $74.41 (market cap $28.60B). The key difference: DexCom, Inc. is far larger — about 49.8× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DNUT | DXCM | |
|---|---|---|
Market Cap | $574.09M | $28.60B |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $89.53 |
52-Week Low | $2.92 | $54.84 |
Enterprise Value | $1.77B | $27.57B |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $3.47, up 0.87% today, with a bearish technical signal and mixed earnings history. The company reported a net loss of $515.77M in 2025 despite a gross margin of 75.56%, while analyst consensus leans bullish with 50% buy ratings. Recent news highlights strategic pivots to capital-light models and seasonal product launches to drive engagement.
Outlook remains challenged by persistent losses and high debt, but positive free cash flow in Q1 2026 and international growth potential offer catalysts. Key risks include execution on turnaround plans and competitive pressures in the consumer staples sector.
DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.
DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
